{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T15:40:04Z","timestamp":1744126804790,"version":"3.40.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,8]]},"DOI":"10.7759\/cureus.81889","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T15:10:27Z","timestamp":1744125027000},"source":"Crossref","is-referenced-by-count":0,"title":["Utility of the Base Editing System for Introducing Drug-Resistant Gene Mutations Into Human Leukemia Cellular Models"],"prefix":"10.7759","author":[{"given":"Thao","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minori","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Nagamachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Kagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shotaro","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiya","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Inukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002220","article-title":"Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia","volume":"135","author":"Li B","year":"2020","unstructured":"Li B, Brady SW, Ma X, et al.. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood. 2020, 135:41-55. 10.1182\/blood.2019002220","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.076786","article-title":"TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy","volume":"98","author":"Chiaretti S","year":"2013","unstructured":"Chiaretti S, Brugnoletti F, Tavolaro S, et al.. TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy. Haematologica. 2013, 98:e59-61. 10.3324\/haematol.2012.076786","journal-title":"Haematologica"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2022.106068","article-title":"Glucocorticoid receptor gene mutations confer glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia","volume":"218","author":"Tamai M","year":"2022","unstructured":"Tamai M, Kasai S, Akahane K, et al.. Glucocorticoid receptor gene mutations confer glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia. J Steroid Biochem Mol Biol. 2022, 218:106068. 10.1016\/j.jsbmb.2022.106068","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nature25186","article-title":"Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia","volume":"553","author":"Tzoneva G","year":"2018","unstructured":"Tzoneva G, Dieck CL, Oshima K, et al.. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature. 2018, 553:511-4. 10.1038\/nature25186","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1124\/molpharm.122.000546","article-title":"CRISPR\/Cas9-mediated induction of relapse-specific NT5C2 and PRPS1 mutations confers thiopurine resistance as a relapsed lymphoid leukemia model","volume":"103","author":"Nguyen TT","year":"2023","unstructured":"Nguyen TT, Tanaka Y, Sanada M, et al.. CRISPR\/Cas9-mediated induction of relapse-specific NT5C2 and PRPS1 mutations confers thiopurine resistance as a relapsed lymphoid leukemia model. Mol Pharmacol. 2023, 103:199-210. 10.1124\/molpharm.122.000546","journal-title":"Mol Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3840","article-title":"Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL","volume":"21","author":"Li B","year":"2015","unstructured":"Li B, Li H, Bai Y, et al.. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. Nat Med. 2015, 21:563-71. 10.1038\/nm.3840","journal-title":"Nat Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00671-9","article-title":"The current state of the art and future trends in RAS-targeted cancer therapies","volume":"19","author":"Punekar SR","year":"2022","unstructured":"Punekar SR, Velcheti V, Neel BG, Wong KK. The current state of the art and future trends in RAS-targeted cancer therapies. Nat Rev Clin Oncol. 2022, 19:637-55. 10.1038\/s41571-022-00671-9","journal-title":"Nat Rev Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong L","year":"2013","unstructured":"Cong L, Ran FA, Cox D, et al.. Multiplex genome engineering using CRISPR\/Cas systems. Science. 2013, 339:819-23. 10.1126\/science.1231143","journal-title":"Science"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03369-x","article-title":"Introduction of the T315I gatekeeper mutation of BCR\/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR\/Cas9 system","volume":"116","author":"Nguyen TT","year":"2022","unstructured":"Nguyen TT, Tamai M, Harama D, et al.. Introduction of the T315I gatekeeper mutation of BCR\/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR\/Cas9 system. Int J Hematol. 2022, 116:534-43. 10.1007\/s12185-022-03369-x","journal-title":"Int J Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27767-6","article-title":"T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR\/Cas9 system","volume":"8","author":"Tamai M","year":"2018","unstructured":"Tamai M, Inukai T, Kojika S, et al.. T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR\/Cas9 system. Sci Rep. 2018, 8:9966. 10.1038\/s41598-018-27767-6","journal-title":"Sci Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli NM","year":"2017","unstructured":"Gaudelli NM, Komor AC, Rees HA, Packer MS, Badran AH, Bryson DI, Liu DR. Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage. Nature. 2017, 551:464-71. 10.1038\/nature24644","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf8729","article-title":"Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems","volume":"353","author":"Nishida K","year":"2016","unstructured":"Nishida K, Arazoe T, Yachie N, et al.. Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science. 2016, 353:6305. 10.1126\/science.aaf8729","journal-title":"Science"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-0774.2005.tb00054.x","article-title":"Establishment and characterization of A novel Philadelphia-chromosome positive chronic myeloid leukemia cell line, TCC-S, expressing P210 and P190 BCR\/ABL transcripts but missing normal ABL gene","volume":"18","author":"Van PN","year":"2005","unstructured":"Van PN, Xinh PT, Kano Y, Tokunaga K, Sato Y. Establishment and characterization of A novel Philadelphia-chromosome positive chronic myeloid leukemia cell line, TCC-S, expressing P210 and P190 BCR\/ABL transcripts but missing normal ABL gene. Hum Cell. 2005, 18:25-33. 10.1111\/j.1749-0774.2005.tb00054.x","journal-title":"Hum Cell"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V60.6.1305.1305","article-title":"Two new acute lymphoblastic leukemia cell lines with early B-cell phenotypes","volume":"60","author":"Findley HW","year":"1982","unstructured":"Findley HW, Jr., Cooper MD, Kim TH, Alvarado C, Ragab AH. Two new acute lymphoblastic leukemia cell lines with early B-cell phenotypes. Blood. 1982, 60:1305-9.","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2356","article-title":"Resistance of t(17;19)-acute lymphoblastic leukemia cell lines to multiagents in induction therapy","volume":"8","author":"Watanabe A","year":"2019","unstructured":"Watanabe A, Inukai T, Kagami K, et al.. Resistance of t(17;19)-acute lymphoblastic leukemia cell lines to multiagents in induction therapy. Cancer Med. 2019, 8:5274-88. 10.1002\/cam4.2356","journal-title":"Cancer Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21738","article-title":"A specific linkage between the incidence of TP53 mutations and type of chromosomal translocations in B-precursor acute lymphoblastic leukemia cell lines","volume":"85","author":"Inukai T","year":"2010","unstructured":"Inukai T, Zhang X, Kameyama T, et al.. A specific linkage between the incidence of TP53 mutations and type of chromosomal translocations in B-precursor acute lymphoblastic leukemia cell lines. Am J Hematol. 2010, 85:535-7. 10.1002\/ajh.21738","journal-title":"Am J Hematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2008.04.011","article-title":"Resistance to TRAIL-induced apoptosis caused by constitutional phosphorylation of Akt and PTEN in acute lymphoblastic leukemia cells","volume":"36","author":"Dida F","year":"2008","unstructured":"Dida F, Li Y, Iwao A, Deguchi T, Azuma E, Komada Y. Resistance to TRAIL-induced apoptosis caused by constitutional phosphorylation of Akt and PTEN in acute lymphoblastic leukemia cells. Exp Hematol. 2008, 36:1343-53. 10.1016\/j.exphem.2008.04.011","journal-title":"Exp Hematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btu048","article-title":"Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases","volume":"30","author":"Bae S","year":"2014","unstructured":"Bae S, Park J, Kim JS. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics. 2014, 30:1473-5. 10.1093\/bioinformatics\/btu048","journal-title":"Bioinformatics"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1089\/crispr.2018.0014","article-title":"EditR: a method to quantify base editing from Sanger sequencing","volume":"1","author":"Kluesner MG","year":"2018","unstructured":"Kluesner MG, Nedveck DA, Lahr WS, Garbe JR, Abrahante JE, Webber BR, Moriarity BS. EditR: a method to quantify base editing from Sanger sequencing. CRISPR J. 2018, 1:239-50. 10.1089\/crispr.2018.0014","journal-title":"CRISPR J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-21-0583","article-title":"Clinical and functional significance of TP53 exon 4-intron 4 splice junction variants","volume":"20","author":"Pinto EM","year":"2022","unstructured":"Pinto EM, Maxwell KN, Halalsheh H, et al.. Clinical and functional significance of TP53 exon 4-intron 4 splice junction variants. Mol Cancer Res. 2022, 20:207-16. 10.1158\/1541-7786.MCR-21-0583","journal-title":"Mol Cancer Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3430","article-title":"MDM2, MDMX and p53 in oncogenesis and cancer therapy","volume":"13","author":"Wade M","year":"2013","unstructured":"Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013, 13:83-96. 10.1038\/nrc3430","journal-title":"Nat Rev Cancer"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.07.030","article-title":"The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia","volume":"16","author":"Klemm L","year":"2009","unstructured":"Klemm L, Duy C, Iacobucci I, et al.. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell. 2009, 16:232-45. 10.1016\/j.ccr.2009.07.030","journal-title":"Cancer Cell"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2022.07.002","article-title":"Complex karyotype with double Philadelphia chromosome and T315I mutation results in blastic phase and extensive extramedullary infiltration in a chronic myeloid leukemia patient","volume":"266-7","author":"Davulcu EA","year":"2022","unstructured":"Davulcu EA, Pekerbas M, Karaca E, Durmaz B, \u00d6zsan N, Ak\u0131n H, Saydam G. Complex karyotype with double Philadelphia chromosome and T315I mutation results in blastic phase and extensive extramedullary infiltration in a chronic myeloid leukemia patient. Cancer Genet. 2022, 266-7:74-80. 10.1016\/j.cancergen.2022.07.002","journal-title":"Cancer Genet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s13039-014-0089-0","article-title":"Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case","volume":"7","author":"Al-Achkar W","year":"2014","unstructured":"Al-Achkar W, Moassass F, Ikhtiar A, Liehr T, Othman MA, Wafa A. Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case. Mol Cytogenet. 2014, 7:89. 10.1186\/s13039-014-0089-0","journal-title":"Mol Cytogenet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.8144","article-title":"Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia","volume":"29","author":"Hof J","year":"2011","unstructured":"Hof J, Krentz S, van Schewick C, et al.. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol. 2011, 29:3185-93. 10.1200\/JCO.2011.34.8144","journal-title":"J Clin Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2532","article-title":"The genomic landscape of hypodiploid acute lymphoblastic leukemia","volume":"45","author":"Holmfeldt L","year":"2013","unstructured":"Holmfeldt L, Wei L, Diaz-Flores E, et al.. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013, 45:242-52. 10.1038\/ng.2532","journal-title":"Nat Genet"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21559-9","article-title":"Programmable C:G to G:C genome editing with CRISPR-Cas9-directed base excision repair proteins","volume":"12","author":"Chen L","year":"2021","unstructured":"Chen L, Park JE, Paa P, et al.. Programmable C:G to G:C genome editing with CRISPR-Cas9-directed base excision repair proteins. Nat Commun. 2021, 12:1384. 10.1038\/s41467-021-21559-9","journal-title":"Nat Commun"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3803","article-title":"Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions","volume":"35","author":"Kim YB","year":"2017","unstructured":"Kim YB, Komor AC, Levy JM, Packer MS, Zhao KT, Liu DR. Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions. Nat Biotechnol. 2017, 35:371-6. 10.1038\/nbt.3803","journal-title":"Nat Biotechnol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone AV","year":"2019","unstructured":"Anzalone AV, Randolph PB, Davis JR, et al.. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019, 576:149-57. 10.1038\/s41586-019-1711-4","journal-title":"Nature"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13475","article-title":"The role of p53 in cancer drug resistance and targeted chemotherapy","volume":"8","author":"Hientz K","year":"2017","unstructured":"Hientz K, Mohr A, Bhakta-Guha D, Efferth T. The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget. 2017, 8:8921-46. 10.18632\/oncotarget.13475","journal-title":"Oncotarget"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16162","article-title":"Application of prime editing system to introduce TP53 R248Q hotspot mutation in acute lymphoblastic leukemia cell line","volume":"115","author":"Nguyen T","year":"2024","unstructured":"Nguyen T, Aida T, Iijima-Yamashita Y, et al.. Application of prime editing system to introduce TP53 R248Q hotspot mutation in acute lymphoblastic leukemia cell line. Cancer Sci. 2024, 115:1924-35. 10.1111\/cas.16162","journal-title":"Cancer Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/354419-utility-of-the-base-editing-system-for-introducing-drug-resistant-gene-mutations-into-human-leukemia-cellular-models","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T15:10:28Z","timestamp":1744125028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/354419-utility-of-the-base-editing-system-for-introducing-drug-resistant-gene-mutations-into-human-leukemia-cellular-models"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.81889","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,8]]}}}